基于人工智能的乳腺X线筛查项目间期癌预防
该研究分析了2006年3月至2018年5月德国西北部2396例间期乳腺癌患者既往筛查乳腺X线片,用AI系统评分。在特异度99.0%操作点,AI检出并正确定位27.5%的假阴性间期癌和12.2%的最小征象间期癌;作者认为AI可辅助放射科医生检出更多癌,降低间期癌率及晚期/转移癌数量。
要点
- AI在特异度99.0%时检出并正确定位27.5%的假阴性间期癌和12.2%的最小征象间期癌。
- 228例回顾可见癌确诊时已晚期/转移,AI在筛查片上检出其中21.1%。
- 真间期癌中AI仅检出并正确定位2.8%后续恶性肿瘤将出现的部位。
核心结论
- AI可辅助放射科医生检出更多癌,从而降低间期癌率及晚期和转移癌数量。
研究设计与样本
- 回顾性分析2006年3月至2018年5月德国西北部2396例间期乳腺癌患者的既往筛查乳腺X线片,所有研究均经乳腺X线参考中心独立放射学复核确认间期癌分类,AI系统对所有研究产生模型评分。
诊断标准与关键数值
- 经放射学复核,间期癌中15.6%为假阴性、19.5%为最小征象、11.4%为隐匿性、53.4%为真间期癌;在特异度99.0%操作点,AI检出并正确定位27.5%(95%CI 23.3-32.3%)的假阴性病例和12.2%(95%CI 9.5-15.5%)的最小征象病例;228例回顾可见病例确诊时已晚期/转移,AI检出21.1%(95%CI 16.3-26.8%);真间期癌中AI检出并正确定位2.8%(95%CI 2.0-3.9%)后续恶性肿瘤将出现的部位。
临床应用与阅片要点
- 作者认为AI可辅助放射科医生检出更多癌,降低间期癌率及晚期和转移癌数量;回顾可见癌中低级别癌和诊断时淋巴结受累者AI检出可能性增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To demonstrate that artificial intelligence (AI) can detect and correctly localise retrospectively visible cancers that were missed and diagnosed as interval cancers (false negative (FN) and minimal signs (MS) interval cancers), and to characterise AI performance on non-visible occult and true interval cancers.
METHOD: Prior screening mammograms from N = 2,396 women diagnosed with interval breast cancer between March 2006 and May 2018 in north-western Germany were analysed with an AI system, producing a model score for all studies. All included studies previously underwent independent radiological review at a mammography reference centre to confirm interval cancer classification. Model score distributions were visualised with histograms. We computed the proportion and accompanying 95% confidence intervals (CI) of retrospectively visible and true interval cancers detected and correctly localised by AI at different operating points representing recall rates < 3%. Clinicopathological characteristics of retrospectively visible cancers detected by AI and not were compared using the Chi-squared test and binary logistic regression.
RESULTS: Following radiological review, 15.6% of the interval cancer cases were categorised as FN, 19.5% MS, 11.4% occult, and 53.4% true interval cancers. At an operating point of 99.0% specificity, AI could detect and correctly localise 27.5% (95% CI: 23.3-32.3%), and 12.2% (95% CI: 9.5-15.5%) of the FN and MS cases on the prior mammogram, respectively. 228 of these retrospectively visible cases were advanced/metastatic at diagnosis; 21.1% (95% CI: 16.3-26.8%) were found by AI on the screening mammogram. Increased likelihood of detection of retrospectively visible cancers with AI was observed for lower-grade carcinomas and those with involved lymph nodes at diagnosis. Among true interval cancers, AI could detect and correctly localise in the screening mammogram where subsequent malignancies would appear in 2.8% (95% CI: 2.0-3.9%) of cases.
CONCLUSIONS: AI can support radiologists by detecting a greater number of carcinomas, subsequently decreasing the interval cancer rate and the number of advanced and metastatic cancers.
引用
- Byng, Strauch, Gnas, et al. AI-based prevention of interval cancers in a national mammography screening program. Eur J Radiol. 2022. PMID: 35512511. doi:10.1016/j.ejrad.2022.110321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。